课题基金 / 基金详情

RECOMBINANT IL-11 PLUS G-CSF VERSUS PLACEBO PLUS G-CSF IN BREAST CANCER

RECOMBINANT IL-11 PLUS G-CSF VERSUS PLACEBO PLUS G-CSF IN BREAST CANCER
重组 IL-11 加 G-CSF 与安慰剂加 G-CSF 在乳腺癌治疗中的比较
批准号：
6246839
负责人：
CAROLYN WASSERHEIT
金额：
$2.39万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-02-12 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6246839
关键词：
breast neoplasms clinical research colony stimulating factor combination cancer therapy cyclophosphamide doxorubicin drug screening /evaluation human subject human therapy evaluation interleukin 11 neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy

项目摘要

项目成果

CAROLYN WASSERHEIT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This Phase II, randomized, multicenter, double-masked study will assess the ability of recombinant human interleukin eleven (NEUMEGA rhIL-11 Growth Factor) to decrease the number of platelet transfusions required by patients with breast cancer during two cycles of high-dose cyclophosphamide/doxorubicin chemotherapy, to assess the safety of rhIL-11 in these patients, and whether anti-IL-11 antibodies are produced in them.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
海外基金